Strategic Clarity for Psychedelic Healthcare’s Mainstream Adoption
Why Attend a Delphi Insight Session?
- Strategic Impact: Maximize your influence on the ethical integration of psychedelic therapies. Our insights support leaders in the psychedelic field and those in finance, healthcare, and government who seek to navigate and shape this emerging landscape, ensuring your efforts contribute to meaningful, systemic change.
- Unparalleled Clarity: Cut through complexity. We deliver concise, actionable intelligence on the psychedelic ecosystem, Delphi’s pivotal role in building its infrastructure, and the critical pathways to responsible mainstream adoption, respecting your time and expertise.
- Bridging Perspectives: Gain a holistic view of how psychedelic therapies can be integrated with established systems. We translate critical information and foster coherence between the psychedelic field and incumbent decision-makers across healthcare, finance, and policy, paving the way for informed action and mutually beneficial outcomes.
Upcoming Delphi Insight Sessions
Join us every first Wednesday of the month as we discuss building a robust infrastructure for psychedelic therapies.
Each 30-minute session, followed by a 15-minute Q&A, offers strategic insights, updates on Delphi’s work, special guests, and opportunities for collaboration.
Time: 11:00 AM MT (1:00 PM ET / 10:00 AM PT)
Insight Session #1 | June 4, 2025
Our first insight session offered an introduction to Delphi, our mission to bridge emerging psychedelic therapies with established healthcare systems, and our vision for their safe, equitable, and effective integration.
We discussed the critical ‘behind-the-scenes’ work required for psychedelic therapies to transition from promise to practice, emphasizing Delphi’s role in creating the ‘connective tissue’ needed for coherence between the psychedelic field and existing systems, such as insurance, government, and healthcare delivery.
The session highlighted key Delphi projects, each designed to provide decision-makers with essential data, non-advocacy education, and ecosystem clarity for the responsible rollout of these transformative treatments.
Insight Session #2 | July 2, 2025
Our second Insight Session built on our introduction to Delphi by exploring how psychedelic therapies can be thoughtfully integrated into mainstream mental health systems. We were honored to be joined by Dr. Tyler Norris, whose decades of work across philanthropy, healthcare, and systems transformation offered a powerful lens for the conversation.
Together with Tyler, we discussed Delphi’s collaborative mindset and focus on bridge-building—not only between psychedelic and incumbent systems, but also between research and implementation. We explored strategic opportunities emerging at the state level in the U.S., the distinct challenges of healthcare adoption in Europe, and the shared priorities across both geographies, from reimbursement pathways to workforce readiness and standards of care.
Insight Session #3 | September 10, 2025
Our third insight session examined reimbursement pathways for psychedelic therapies in Europe, explaining why coverage will determine whether these treatments become accessible, trusted, and equitable at scale.
We walked through current signals and mechanics, making the case for modified or conditional reimbursement tied to real-world evidence, supported by payer-relevant endpoints, agreed comparators, health-economic modeling, appropriate codes and rates, and planned clinic capacity.
The session introduced RIPE (Reimbursement and Infrastructure for Psychedelics in Europe), a structured, multi-year roadmap and coalition to build the plumbing for equitable access.
Insight Session #4 | October 1, 2025
Our fourth insight session examined how psychedelic use is actually happening across the United States today, introducing a comprehensive national survey designed to track patterns, motivations, and mental health profiles in real time.
We were joined by Kate Reynolds, Director of Research at Rocky Mountain Poison and Drug Safety, who presented NSIHT (National Survey Investigating Hallucinogenic Trends), a rigorous, scalable tool built specifically to capture the complexity of psychedelic use that existing data systems miss.
The session underscored how real-world evidence differs from clinical trials, capturing polysubstance patterns, co-use with alcohol and cannabis, current symptom profiles beyond formal diagnoses, and emerging phenomena like psychedelic tourism to states with regulated programs.
Insight Session #5 | November 5, 2025
Our fifth insight session focused on the emerging role of ibogaine therapy in U.S. healthcare, framed through a rare combination of policy analysis, clinical implementation realities, and lived experience. The session centred on the profound therapeutic potential of ibogaine for addiction, trauma-driven conditions, and traumatic brain injury.
Lia Mix, CEO of Delphi, shared both her professional assessment of ibogaine’s viability and her own recent treatment experience. Drawing on clinical monitoring protocols, neurophysiological data (including pre-/post-QEEG), and insights from frontline care delivery, she illustrated why ibogaine may represent a distinct class of neuroplastogen with a uniquely long recovery window.
The session highlighted the real-world policy implications: scalable safety architecture, the opportunity to retrofit existing behavioural-health and medical-care infrastructure, and the need for payer-ready frameworks to guide adoption. It culminated in the announcement of the Ibogaine Healthcare Policy Institute (IHPI), a new Delphi initiative dedicated to building the actuarial, clinical, and operational clarity required for responsible system-level evaluation of ibogaine therapy.
Insight Session #6 | January 7, 2026
Our sixth Insight Session featured a conversation with Leith States, MD, MPH, former Acting Assistant Secretary for Health and Chief Medical Officer at the U.S. Department of Health and Human Services (HHS). The discussion explored how psychedelic-assisted therapies are moving from emerging evidence into real-world systems, and what responsible implementation requires from public health, policy, and healthcare leadership.
States reflected on the leadership principles that shaped his public service, including a focus on stewardship for the most vulnerable and a preventive-medicine lens for improving population-level outcomes. He also described how he became involved in federal coordination on psychedelic-assisted therapies, emphasizing the importance of pairing clinical-trial evidence with stakeholder proximity and lived-experience insights to understand risks, readiness, and public trust.
The session examined why psychedelic-assisted therapies are meaningfully different from conventional behavioral health approaches, including their reliance on preparation, integration, and workforce capability rather than chronic dosing alone.
Insight Session #7 | February 4, 2026
Our seventh Insight Session focused on the practical mechanics of advancing psychedelic medicine through the U.S. federal system, viewed through the lens of legislative strategy, institutional design, and healthcare implementation.
The session centred on how psychedelic policy is increasingly moving beyond awareness-building and into the harder work of fitting emerging treatments into existing regulatory, clinical, and reimbursement structures. Melissa Lavasani, Founder and CEO of the Psychedelic Medicine Coalition (PMC), the only Washington, D.C.-based nonprofit dedicated to advancing psychedelic-assisted therapies at the federal level, joined us this session.
Drawing on her policy background and personal experience with postpartum depression, Melissa outlined how the federal conversation has matured: from a countercultural framing to questions of jurisdiction, liability, workforce capacity, institutional oversight, and evidence generation.
Insight Session #8 | March 4, 2026
In this conversation, Lia Mix speaks with Britt Rollins, co-founder of the National Psychedelics Association, about the practical infrastructure needed to support the growth of legal psychedelic care in the United States. The discussion begins with the origins of the NPA and its central mission: lowering the cost of providing psychedelic-assisted care so that these services can become more accessible, sustainable, and safe for both practitioners and participants.
Rollins explains how the association has evolved by listening closely to service centers and facilitators in Oregon and Colorado. He outlines the operational barriers facing the field, from banking and payment processing to awareness, advocacy, and regulatory design. A major focus of the conversation is the NPA’s new professional malpractice and general liability insurance product, which he describes as a critical step toward reducing financial risk, enhancing consumer protection, and strengthening the foundation for long-term market development.
